{"nctId":"NCT01723072","briefTitle":"Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","startDateStruct":{"date":"2013-01-23","type":"ACTUAL"},"conditions":["Chronic Spontaneous Urticaria","Angioedema"],"count":91,"armGroups":[{"label":"1 Omalizumab","type":"EXPERIMENTAL","interventionNames":["Biological: Omalizumab"]},{"label":"2 Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Omalizumab","otherNames":["IGE025"]},{"name":"Placebo","otherNames":["Placebo for Omalizumab"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of chronic spontaneous urticaria (CSU) refractory to H1-antihistamine treatment\n* Presence of itch an hives for more than 6 weeks\n* UAS7 score of more than 14 (range 0-42)\n* Patient has history of insufficient response to 4x of the approved dose of H1-antihistamines\n* CSU diagnosis for more than 6 months\n* Angioedema at least 4x in the last 6 months\n\nExclusion Criteria:\n\n* Patients with non urticaria associated angioedema\n* History of hypersensitivity to omalizumab or the rescue medication or to drugs of similar chemical structure\n* Evidence of parasitic infection\n* Previous treatment with omalizumab within the last 6 months prior to screening\n* History of anaphylactic shock\n* Woman who are pregnant or breast feeding\n* Other protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline Using Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Total Scores During the Study: Unadjusted Analysis and ANCOVA (LOCF) (FAS)","description":"The CU-Q2oL is a questionnaire that measures the relative burden of chronic urticaria on subjective well-being. It consists of 23 questions in 3 domains (symptoms, general impairment, difficulties and problems due to urticaria). Participants are asked to respond how much they are troubled by each problem on a 5-point Likert scale (1= not at all to 5= very much). An overall score is calculated and normalized to a scale of 1 to 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.5","spread":"21.3"},{"groupId":"OG001","value":"-6.4","spread":"15.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.1","spread":"21.8"},{"groupId":"OG001","value":"-12.1","spread":"20.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.4","spread":"23.7"},{"groupId":"OG001","value":"-16.2","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.1","spread":"24.2"},{"groupId":"OG001","value":"-13.9","spread":"17.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.9","spread":"23.0"},{"groupId":"OG001","value":"-14.7","spread":"19.2"}]}]}]},{"type":"SECONDARY","title":"Number of Angioedema Burdened Days by Study Phase (Observed Cases With Imputation)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"3.9"},{"groupId":"OG001","value":"6.8","spread":"4.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":"19.5"},{"groupId":"OG001","value":"49.5","spread":"50.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"9.1"},{"groupId":"OG001","value":"12.8","spread":"16.2"}]}]}]},{"type":"SECONDARY","title":"Mean Time Interval Between Successive Angioedema Episodes of the First 15 Episodes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":"41.63"},{"groupId":"OG001","value":"7.8","spread":"14.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":"19.52"},{"groupId":"OG001","value":"7.2","spread":"10.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":"50.73"},{"groupId":"OG001","value":"8.3","spread":"13.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":"23.87"},{"groupId":"OG001","value":"8.6","spread":"20.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":"20.54"},{"groupId":"OG001","value":"13.6","spread":"30.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"22.11"},{"groupId":"OG001","value":"7.5","spread":"11.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":"29.41"},{"groupId":"OG001","value":"9.1","spread":"17.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"15.05"},{"groupId":"OG001","value":"8.0","spread":"12.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"20.16"},{"groupId":"OG001","value":"8.7","spread":"12.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"13.02"},{"groupId":"OG001","value":"8.5","spread":"10.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"9.42"},{"groupId":"OG001","value":"9.4","spread":"13.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"4.47"},{"groupId":"OG001","value":"4.3","spread":"4.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"3.02"},{"groupId":"OG001","value":"7.3","spread":"4.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"9.96"},{"groupId":"OG001","value":"10.1","spread":"11.86"}]}]}]},{"type":"SECONDARY","title":"Change of Angioedema Activity Score (AAS) Total Week Sum Scores: Unadjusted Analysis and ANCOVA (Observed Cases With Imputation)","description":"A cumulative activity score, evaluated in the screening period and throughout the study. The records each evening on a daily basis symptoms of itch and hives into a patient diary. min. score = 0 ; max. score= 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":"20.0"},{"groupId":"OG001","value":"-5.0","spread":"18.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":"22.4"},{"groupId":"OG001","value":"-9.0","spread":"22.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.3","spread":"21.6"},{"groupId":"OG001","value":"-16.9","spread":"21.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.6","spread":"21.5"},{"groupId":"OG001","value":"-10.8","spread":"21.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.6","spread":"18.4"},{"groupId":"OG001","value":"-15.3","spread":"20.8"}]}]}]},{"type":"SECONDARY","title":"Diameter: Acute Swelling Episodes Within the Screening Period (Week -2 to -1)","description":"data points per group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Diameter: Acute Swelling Episodes at End of Treatment (Weeks 25 to 28)","description":"data points per group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Diameter: Acute Swelling Episodes at End of Follow-up(Weeks 33 to 36)","description":"data points per group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Shortness of Breath: Acute Swelling Episodes Within the Screening Period (Weeks -2 to -1)","description":"data points per group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"264","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Shortness of Breath: Acute Swelling Episodes at End of Treatment Period (Weeks 25 to 28)","description":"data points per group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"195","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Shortness of Breath: Acute Swelling Episodes at End of Follow-up Period (Weeks 33 to 36)","description":"data points per group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change of AE-Q2oL Scores From Baseline to Week 28: Unadjusted Analysis and ANCOVA (Observed Cases)","description":"The AE-Q2oL is a questionnaire for patients suffering from angioedema. It consists of 29 questions relevant to angioedema and its specific impact on quality of life. Patients are asked to respond how much they are troubled be each problem on a 5-point Likert scale (1= does not apply to 5= very much). An overall score is calculated and a higher score indicates lower quality of life. A negative change score (week 28 score minus baseline score) indicates improvement.\n\nEach AE-QoL question has 5 answer options (scored 1-5), with lower and higher scores indicting less and more adverse impact, respectively. The total score is calculated, which is then transformed into a linear scale that ranges from 0 to 100, with a score of 100 indicating the worst possible impairment of HRQoL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.5","spread":"20.4"},{"groupId":"OG001","value":"-10.3","spread":"21.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.4","spread":"23.8"},{"groupId":"OG001","value":"-20.4","spread":"27.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.1","spread":"26.5"},{"groupId":"OG001","value":"-28.8","spread":"22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.4","spread":"25.7"},{"groupId":"OG001","value":"-24.2","spread":"24.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.2","spread":"26.4"},{"groupId":"OG001","value":"-24.6","spread":"23.3"}]}]}]},{"type":"SECONDARY","title":"Rescue Medication During the Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Days of Rescue Medication During the Treatment Period","description":"data points per group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"507","spread":null},{"groupId":"OG001","value":"787","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"403","spread":null},{"groupId":"OG001","value":"524","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]},{"type":"SECONDARY","title":"Days of Rescue Medication During the Follow-up Period","description":"data points per group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Change of UAS7 Total Scores From Baseline to Week 28: Unadjusted Analysis and ANCOVA (Observed Cases)","description":"The UAS7 is the sum of urticaria activity scores over a seven day period. The possible range of the weekly UAS7 score is 0-42. 0 means complete response and a better outcome and 42 means no response and a worse outcome.\n\nComplete UAS7 response is defined as UAS7=0. The UAS7 is the sum of the Hive Severity Score over seven days (HSS7) and the Itch Severity Score over seven days (ISS7) . The Hive Severity Score has a scale of 0 (none) to 3 (intense/severe). Complete hives response is defined as HSS7=0. The Itch Severity Score has a scale of 0 (None) to 3 (Severe (difficult to tolerate)). Complete itch response is defined as ISS7=0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.6","spread":"13.3"},{"groupId":"OG001","value":"-3.0","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.4","spread":"14.3"},{"groupId":"OG001","value":"-4.4","spread":"13.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.0","spread":"15.0"},{"groupId":"OG001","value":"-7.2","spread":"14.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.8","spread":"14.8"},{"groupId":"OG001","value":"-6.5","spread":"13.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"15.3"},{"groupId":"OG001","value":"-6.2","spread":"13.3"}]}]}]},{"type":"SECONDARY","title":"Change of DLQI Scores From Baseline to Week 28: Unadjusted Analysis and ANCOVA (Observed Cases)","description":"change in Dermatology Quality of Life Index scores\n\nThe DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). \"Not relevant\" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"7.3"},{"groupId":"OG001","value":"-2.4","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"7.5"},{"groupId":"OG001","value":"-3.9","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.5","spread":"8.4"},{"groupId":"OG001","value":"-5.1","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.5","spread":"8.3"},{"groupId":"OG001","value":"-5.6","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"8.6"},{"groupId":"OG001","value":"-5.4","spread":"8.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":44},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Urticaria","Back pain"]}}}